Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is efficacy. The primary efficacy endpoint of this study
is a comparison of the overall survival of subjects treated with CCI-779 [Temsirolimus],
administered intravenously [IV] once weekly and the combination of CCI-779, administered IV
once weekly with Interferon Alfa [IFN alfa] subcutaneously [SC] three times per week [TIW],
compared with the overall survival of subjects treated with IFN alfa (SC TIW) alone, in
poor-prognosis subjects with advanced RCC.